Mark Mayeda

Radiation Oncology | @BostonCollege @uhmed @ColumbiaRadOnc @NYPhospital Alum | tweets= mine

[PDBrown @PDBrownOnc]

🚨🚨Randomized Trial GBM Tumor Treating Fields (TTF) upfront with RT+TMZ and maintenance TTF+TMZ vs. RT/TMZ followed by maintenance TTF+TMZ🚨

NO benefit upfront TTF HR 0.953; p=0.519
Maintenance TTF remains the standard of care

[Journal of Clinical Oncology @JCO_ASCO]

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer.

Read full article. https://t.co/7WGW5FItmi

[Dr. Andrew Loblaw @DrAndrewLoblaw]

@weeloonong leads pub in @EurUrolOncol for #PATRIOT (#SBRT weekly vs every other day treatment for favourable risk #prostatecancer )

No stat diff in bioc fail (mFU of 91mo)

Planning to combine with @ZilliThomas #NOVALIS study (same design)

free link👉https://t.co/Bq1vHzBUpI

[Daniel E Spratt @DrSpratticus]

SBRT superior to thermal ablation (and non invasive without tumor size limitations). This is without even accounting for use of advanced technology with adaptive RT or surface monitoring and gating, etc.

Fortunate to have many excellent urologists @LPonsky who have helped champion early studies.

@jeshoag @randy_vincejr @AdamCalaway

[Nicholas van As @nickva1]

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦@DrTolan⁩ @alison_tree⁩ ⁦@cpeedell⁩ @DrAndrewLoblaw⁩ ⁦@EmmaHall71⁩ @ProfJOSullivan⁩ https://t.co/HlFxb3jegQ

[Clive Peedell @cpeedell]

This is the beginning of the end for #prostatectomy in localised #prostatecancer. In future, prostatectomy should be reserved for patients with severe LUTS and large prostates. Patients deserve an honest discussion about PACE-A & Protect Trial results, & surgical learning curves

[Stefano Arcangeli @StAr_MCM74]

🚀groundbreaking news🎳❗️
➡️ every PCa patient should be aware of these results before choosing the treatment

👏@nickva1 @alison_tree @EmmaHall71 🇬🇧

#ProstateCancer #SBRT

[Dr. Andrew Loblaw @DrAndrewLoblaw]

Well done (again) @nickva1 and the #UKCR @royalmarsdenNHS team!

[Mark Mayeda @MMayedaMD]

@SbrtSean Congrats from Hawaii!

[Dr. Andrew Loblaw @DrAndrewLoblaw]

In PACE-B (@nickva1, #ASTRO23), only 3.5% of patients recurred after 5y. In our @Sunnybrook #SBRT series only 5% of fav int risk patients recurred after 10y (Kennedy T, #ESTRO24)

Maybe you could clarify what you meant by “common occurrence”?

[Krishan Jethwa @KrishanJethwa]

🚨🚨RTOG 0848🚨🚨

Anatomically resectable PDAC randomized postoperatively
1st randomization:

Gemcitabine +/- erlotinib (no benefit with erlotinib)

🔥2nd Randomization🔥
+/- Chemoradiation, 50.4 Gy/28 fx + cape

✅⬆️ DFS w/ ☢️
✅N0, ⬆️DFS and OS (5y 48% vs 29%) w/ ☢️
#asco24

[Mark Mayeda @MMayedaMD]

@DrWuRadOnc @MGallittoMD So proud

[Matthias Guckenberger @Mat_Guc]

DOSIS - RCT in pts with painful vertebral mets
Hypothesis: improved LC -> durable pain response
First randomized trial with 6 mo pain reduction as prim endpoint
N=63 pts randomized to SBRT vs conv. RT
Significant benefit of SBRT: 69.4% vs. 41.9% (p=0.02)
https://t.co/5K6ld5dRKa

[Mark V. Mishra @MarkMishraMD]

Pleased to share our secondary analysis of @NRGonc CC001 evaluating heterogeneity of treatment effect for patients receiving HA-WBRT. https://t.co/aGkKHMoUjG

@OncoAlert #btsm #lcsm

[Drew Moghanaki @DrewMoghanaki]

The standard of care for stage III NSCLC changes once again;

Say goodbye to Durvalumab for patients with mEGFR (ex19del & L858R). #radonc

https://t.co/9KhukJ6iVL

[Jeremie Calais @CalaisJeremie]

In the #PSMA #PETimaging arm of the randomized PSMA-SRT trial @UCLA and @UCSF, M1 disease was detected in ~10% and there was 18% more treatment escalation than in the control arm. Will this lead to improved PSA outcomes? Analysis is planned for 2025.
https://t.co/OuEz4C9YzP

[Danny Vesprini @dr_vesi]

Happy to share our experience of primary ablative radiotherapy for #breastcancer in people that are not surgical candidates. Safe and effective!

Lots of people to @ but special mention to @DMoorePalhares @hanbo_chen @benazir_mir
@Sunnybrook @UofTDRO

https://t.co/pk9iBRiPNV

[Mark Mayeda @MMayedaMD]

@ColumbiaRadOnc @MGallittoMD @RSNA @ASCO So proud of you Matthew! -zad

[PDBrown @PDBrownOnc]

Bone Met week 2/5
Post-op RT after surgical stabilization, should you treat entire hardware?
YES
https://t.co/TyuC83FkG3

[Erin Gillespie, MD MPH @ErinGillespieMD]

Radiation to asymptomatic bone metastases reduces SREs (incl fractures, cord compression).

Primary results of our phase 2 RCT ⚖️ were published (below).

If you don’t have access to the full manuscript 📑, please DM me. 🙏 #radonc #medonc